To determine whether and how germline DNA-repair gene mutations influence clinical outcomes to abiraterone or enzalutamide in patients with castration-resistant prostate cancer (CRPC), we performed germline genotyping for 50 DNA-repair genes using blood samples from 172 patients with CRPC beginning first-line systemic therapy with abiraterone or enzalutamide. We discovered that the presence of germline DNA-repair gene defects (particularly mutations in the BRCA1/2 and ATM genes) were associated with better outcomes to abiraterone and enzalutamide.
Bibliographical noteFunding Information:
Funding/Support and role of the sponsor: This work is supported by National Institutes of Health Grants R01 CA185297 and P30 CA006973, Department of Defense Prostate Cancer Research Program Grants W81XWH-15-2-0050 and W81XWH-12-1-0605, the Commonwealth Fund, and Johns Hopkins Prostate SPORE Grant P50 CA058236, and by the Patrick C. Walsh Fund and the Prostate Cancer Foundation. The sponsors played no direct role in the study.
- DNA repair